

Appendix

The full membership of the C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee is as follows: Chao Family Comprehensive Cancer Center: Frank L. Meyskens, Jr., M.D. (Co-Chair); AstraZeneca Oncology: Gregory A. Curt, M.D. (Co-Chair), Joseph D. Purvis, M.D.; University of Michigan Health System: Dean E. Brenner, M.D.; University of Texas M. D. Anderson Cancer Center: Powell H. Brown, M.D., Ph.D., Ernest Hawk, M.D., M.P.H., Scott M. Lippman, M.D.; National Cancer Institute: James Crowell, PhD, Gary J. Kelloff, M.D., Samir N. Khleif, M.D., Eva Szabo, M.D.; Cancer Research UK: Jack Cusick, M.D.; Arizona Cancer Center: Robert T. Dorr, Ph.D.; Pfizer, Inc.: Craig Eagle, M.D.; University of Washington: Scott S. Emerson, M.D., Ph.D.; University of Pittsburgh School of Medicine: Olivera Finn, Ph.D.; OSI Pharmaceuticals, Inc.: Neil Gibson, Ph.D.; Abbott Laboratories, Inc.: Gary Gordon, M.D., Ph.D.; Intrexon Corporation: Ronald B. Herberman, M.D.; University of California, Irvine: Claude L'Enfant, M.D., Christine E. McLaren, Ph.D.; American Association of Cancer Research: Mark Mendenhall, J.D.; Eli Lilly and Company: Colleen Mockbee, R.Ph.; GlaxoSmithKline: Clet Niyikiza, Ph.D; Nodality, Inc.: David R. Parkinson, M.D.; CCS Associates: Caroline C. Sigman, Ph.D.; Lombardi Comprehensive Cancer Center, Georgetown University: Louis M. Weiner, M.D.; Geisinger Medical Clinic: Victor Vogel, M.D.; RCY Medicine: Robert C. Young, M.D; Subcommittee Staff Support: Alison P. Smith, B.A., B.S.N., R.N.